Clinical trial NCT06319391: Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation
Official title: Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Complete and Accurate Statistical Data of 60 Patients
CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately
Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients
According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the Cases and Grading of Postoperative Acute Kidney Injury in 60 Patients Were Counted
Scientific and Rigorous Statistical Analysis of Data
Keywords: CYP3A5
gene polymorphism
tacrolimus
acute kidney injury
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2024-03-20
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 60 patients receiving liver transplantation at the center of Qianfoshan Hospital in 2022.01-2023.06

Brief summary: Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose according to body weight, sometimes low dose will cause graft rejection of patients, or high dose will lead to infection and liver and kidney toxicity and other adverse reactions. Moreover, the conventional drug testing can not fully reflect the efficacy of tacrolimus, and there are shortcomings of lag, experience and passivity. FK506 is metabolized primarily by cytochrome P450 member 3A5 in the liver and intestines. CYP3A5\*3 is the most important factor determining the expression level of CYP3A5. This mutation can cause variable shear and produce unstable protein, so that patients carrying CYP3A5\*3/\*3 gene do not express CYP3A5. Acute kidney injury is a common and important complication after liver transplantation. Despite recent advances in organ preservation, surgical techniques, and immunosuppressive protocols, the incidence of AKI after orthotopic liver transplantation remains high. AKI has a significant impact on both short - and long-term prognosis of orthotopic liver transplantation recipients. Studies have shown that orthotopic liver transplantation recipients with AKI have significantly higher mortality rates in hospital, at 28 days and at 1 year after surgery than those without AKI. In this study, the relationship between donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration was investigated, and the effect of donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration on acute kidney injury after liver transplantation was investigated. To provide guidance for individual administration of gene-directed tacrolimus in patients, and provide basis for prevention and reduction of postoperative acute kidney injury in liver transplantation patients.


Eligibility criteria: Inclusion Criteria:

1. Patients undergoing orthotopic liver transplantation in our center.
2. The postoperative immunosuppression regimen was tacrolimus、methylprednisolone and balipremumab for injection in all cases,and no drugs that interacted with tacrolimus were used.
3. The postoperative follow-up time was greater than 6 months and no serious rejection occurred during the follow-up period.

Exclusion Criteria:

1. Combined organ transplantation.
2. liver transplant patients on other immunosuppressive regimens.
3. Preoperative CKD or need RRT.
4. Preoperative serum creatinine (SCr) \> 133 mol/L.
5. Loss of follow-ups.

Primary outcomes:
measure: Fk506
timeFrame: 1-28 days postoperatively
measure: Scr
timeFrame: 1-28 days postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
state: Shandong
Study officials:
affiliation: Party
name: Liziqiang Liziqiang, Doctor
role: STUDY_DIRECTOR
References: